| MRSN |
Mersana Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
5.48% |
$2.12M |
-$41.9M |
274K |
-95.2% |
Schonfeld Strategic Advisors LLC |
Sep 30, 2025 |
| TERN |
Terns Pharmaceuticals, Inc. |
Common Stock, par value $0.0001 per share |
4.93% |
$12.6M |
-$2.71M |
4.31M |
-17.8% |
Schonfeld Strategic Advisors LLC |
Mar 31, 2025 |
| SKYE |
Skye Bioscience, Inc. |
Common Stock, par value $0.001 per share |
3.6% |
$4.44M |
-$2M |
1.12M |
-31% |
Schonfeld Strategic Advisors LLC |
Jun 30, 2025 |
| APLT |
Applied Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
3.3% |
$1.82M |
-$1.6M |
4.68M |
-46.7% |
Schonfeld Strategic Advisors LLC |
Mar 31, 2025 |
| RVPH |
Reviva Pharmaceuticals Holdings, Inc. |
Common Stock, par value $0.0001 per share |
2.82% |
$1.16M |
|
1.31M |
|
Schonfeld Strategic Advisors LLC |
Dec 31, 2024 |
| FATE |
Fate Therapeutics, Inc. |
Common Stock, par value $0.001 per share |
0.82% |
$1.05M |
-$7.68M |
938K |
-88% |
Schonfeld Strategic Advisors LLC |
Jun 30, 2025 |